StockWatch
·
MUFIN GREEN FINANCE · Q2 FY27 · THE VERDICT

170% PAT growth masks a tightening H2 path to full-year guidance

Mufin delivered a sharp 170% PAT jump and a bullish strategic pivot to digital lending. But its full-year guidance now hinges on an H2 acceleration the call didn't justify — the real debate is whether this quarter's momentum will persist.

Q2 FY27 resultsMUFINMufin Green Finance Ltd17 Nov 2026 · 6 min read

On the headline, Mufin's Q2 profit is a standout: PAT at ₹15.1 Cr is up 170% year-over-year and the company has swung hard to profitable digital lending, with net profit margin at 16.8%. Revenue growth of 62% confirms strong origination momentum. For a quarter alone, this is unambiguously bullish. But the story shifts when you place H1 numbers (₹29.1 Cr PAT year-to-date) against full-year guidance of ₹80–90 Cr. At the current run rate, Mufin needs to generate ₹51–61 Cr in H2—a 1.75–2.1x jump from Q2's organic pace—to stay on track. The company did not restate or narrow this guidance on the call, and offered no concrete mechanism for the acceleration. That gap, between reported momentum and guidance tightness, is the quarter's real tension.

Q2 PAT delivered

₹15.1 Cr

+170% YoY; +7.5% QoQ

H1 PAT to date

₹29.1 Cr

32–36% of FY27 target (₹80–90 Cr)

H2 PAT needed

₹51–61 Cr

1.75–2.1x required growth

Profitability quality: cost discipline delivered

The profit jump is not a one-time item or accounting pop—it's anchored in real cost reduction and operating leverage. Interest expense spiked 103.7% year-over-year (driven by an EMI liability holding), but interest income outpaced it at 80.2% growth, and net interest income still climbed 52.4%. More tellingly, the company reduced its cost of borrowing to 11.17% from 13.80%, a 265 basis-point win that translates directly to margin expansion. This is structural, not cyclical. Operating leverage is real: PAT growth of 169.5% outran OpEx growth of 27.7%. Mufin's move to digital lending and away from climate financing—a topic management had euphemistically called a 'mistake'—has freed capital and discipline that now flows to the bottom line.

Claims on the call vs. what holds up

Verdict on key management claims

AUM tracking ₹2,500 Cr FY27 target

Supported

H1 at ₹1,766 Cr is 70.6% of target; requires ~11% H2 growth for flat YoY H2 (achievable on current origination pace)

FY27 PAT guidance ₹80–90 Cr on track

Overstated

H1 ₹29.1 Cr is 32–36% of target; Q2 grew 7.5% QoQ, far below the 1.75–2.1x pace needed in H2

Borrowing costs reduced to 11.17% from 13.80%

Supported

265 basis-point reduction confirmed; achieved via PSU bank onboarding (State Bank, IOB, Union, IDBI) alongside existing funders

NPA improved sharply, gross 1.91%→1.77%, net 1.63%→1.50%

Supported

Improvement confirmed; of ₹30 Cr total NPA, ₹29 Cr is legacy EV (99%, already provisioned), ₹1 Cr from new products

Digital lending now 44% of AUM

Supported

Mediclaim ₹687 Cr (38.9%), Salary Saathi ₹91 Cr (5.1%); combined ₹778 Cr on ₹1,766 Cr AUM base

What changed on this call

Mufin's business mix has undergone a sharp pivot. Climate financing, which the company had bet on for years, is now a retreating legacy book of ₹160–180 Cr (down from prior focus). That ₹25 Cr pain remaining in vehicle and battery loans is expected to stabilize; the 99% of NPA that is legacy EV portfolio is already reserved for. In its place, digital lending has surged to 44% of AUM, anchored on two products: Mediclaim (insurance premium financing, ₹687 Cr, the market's clear leader despite 50+ rivals) and Salary Saathi (government employee personal loans, ₹91 Cr, launched February 2026 and gaining traction rapidly). Arthum, a 20% equity stake in a workforce financing platform that uses a PPI wallet model, is nascent but positioned in a structural opportunity (₹20–30k Cr p.a. market, only 4 PPI licence holders in India).

On the regulatory front, Mufin was approved for an RBI AD-II (Authorised Dealer Category II) licence—a forex dealer slot—just 2 days before the earnings call. The route was unusual (direct application, not the standard FFMC ladder), which management read as regulatory confidence. Revenue impact is deferred to FY28, but the approval signals a widening product funnel.

On infrastructure, the company has upgraded visibly: hired senior CISOs (Harish Arora from Ambit, Amit Sharma from SBI Cards), migrated servers to AWS, deployed SentinelOne, and committed to quarterly VAPT audits. The Middle Layer NBFC compliance move (new RBI rules for entities at Mufin's scale) will add modest compliance capex, but management is ahead of the curve.

The bull-bear ledger

  • Profitability inflection is real: 170% PAT growth, 16.8% NPM, cost of borrowing down 265 bps

  • Strategic pivot to digital lending + Arthum workforce financing addresses structural markets

  • NPA quality improving (1.77% gross), legacy climate book shrinking, new-product NPA isolated (₹1 Cr)

  • AUM trajectory on pace for ₹2,500 Cr FY27 target (70.6% by H1); origination momentum strong

  • FY27 PAT guidance of ₹80–90 Cr now requires 1.75–2.1x H2 growth vs 7.5% QoQ current pace; no H2 narrowing or roadmap on call

  • Mediclaim market now has 50+ competitors; product margins under pressure despite claimed market share and service edge

  • Climate tail ₹25 Cr pain could slip if EV market deteriorates; retention risk on junior team scaling

  • FY28 guidance vague ('golden period'); Arthum and new products early-stage; execution risk on new verticals

Risks, ranked by how much they should concern a holder

Top risks and severity

PAT guidance path tightens in H2

High

H1 is only 36% of FY27 target (₹80–90 Cr); Q2 grew 7.5% QoQ, far below the 1.75–2.1x needed. If H2 disappoints, full-year miss and credibility dent; stock reprices lower.

Mediclaim market commoditization

Medium

50+ competitors replicating Mediclaim; product margin erosion expected. Mufin claims market size (20–25% p.a. growth) can support all players, but yields under pressure. ₹687 Cr (38.9% of AUM) is concentrated; repricing risk.

Cyber security as platform scales

Medium

5–10 minute digital onboarding attracts hacker attention. Mufin recently hired CISOs and upgraded to AWS + SentinelOne, but infrastructure risk elevated as they scale digital. Breach or regulatory penalty could spike OpEx or dent brand.

Climate financing tail slippage

Low

₹25 Cr pain remaining in ₹160–180 Cr book. If EV market deteriorates, slippage could exceed expectations. Mitigated by 99% of NPA being legacy (already provisioned) and EV book shrinking.

Arthum and new products execution

Low

Arthum (workforce financing) early-stage; market large (₹20–30k Cr p.a.) but only 4 PPI licence holders. Execution on insurance partner integration, unit economics, and scale unproven. FY28 is claimed 'golden period' but no quantified guidance.

How the street is positioned

Mufin's stock is trading at ₹139.27 as of November 17, 2026, in a bullish trend (above SMA20 at ₹136.44, SMA50 at ₹135.13, SMA200 at ₹124.07). The 52-week range is ₹95–₹145; at the all-time high of ₹274.4, the stock has fallen 49.25%—a sharp drawdown, but the current price sits 46.6% above the 52-week low, suggesting the market is pricing in a recovery narrative. RSI is neutral at 54.7, volume normal.

Institutional ownership tells a nuanced story. FII have trimmed from 2.26% in Q1 FY27 to 1.80% in Q2 (−46 bps), signalling caution or profit-taking. DII remain flat at 10.05%. Promoter stake is stable at 47.30%, showing no dilution concerns from management's view. Recent bulk/block deals in early November (Nivesh Consultancy bought ₹833k shares at ₹135.59, then sold ₹1,085k at ₹134.10; Three Words Capital sold ₹1,090k at ₹131.51; Aakanksha Satyen Mamtora bought ₹1,120k at ₹131.59) show mixed conviction—no promoter or insider-linked selling near the highs, but tactical trading around ₹131–135. The absence of concerning insider selling near the ATH is reassuring.

The market's own verdict on the print is mixed. A 49% drawdown from ATH, combined with a 46% recovery off lows, suggests the street is in debate—the fundamental case for profitability and digital pivot is accepted, but the guidance path is questioned. The FII exit, modest in magnitude but directional, hints that overseas investors are waiting for clarity on H2 momentum before re-entering. The current price is a reasonable entry point for holders willing to weather H2 execution risk; it is not a screaming bargain.

The debate

The honest read: Mufin has delivered a credible Q2 and a bullish strategic pivot. Profitability quality is high and cost discipline is durable. But the company's full-year guidance now hinges on an H2 acceleration that the call did not justify. Management is confident ('on track', 'no issue') but offered no mechanism for the 1.75x jump needed. The debate is real: Can Mufin sustain momentum (and accelerate) into H2, or does Q2 mark a peak and guidance gets revised lower? The stock's current price (46% recovery, still -49% from ATH) reflects this honest uncertainty. For holders, the Q3 print will resolve the debate—if Q3 PAT grows 15%+ QoQ, the H2 path opens up and the bull case compounds. If Q3 grows 5–10% QoQ, the guidance miss becomes likely and re-rating down is warranted.

What to watch next

Three things that resolve the debate
  • 1 · Q3 PAT inflection (critical)

    The make-or-break metric. If Q3 PAT grows 15%+ QoQ from Q2's ₹15.1 Cr, momentum is real and the ₹80–90 Cr FY27 target is back on table. If Q3 grows 5–10% QoQ, the H2 path breaks and a guidance miss becomes likely. This is the pivot point.

  • 2 · Disbursement run rate and digital AUM mix

    Q2 disbursements were ₹590 Cr (+31% QoQ). Watch Q3–Q4 for sustained 20%+ QoQ growth and whether digital products (Mediclaim, Salary Saathi, Arthum) are maintaining yields under 50+ competitor pressure. Pricing erosion in Mediclaim would signal margin headwind.

  • 3 · RBI Middle Layer NBFC compliance capex and Arthum scaling

    Infrastructure investments (AWS, SentinelOne, vendor onboarding) are rising. Watch Q3–Q4 for OpEx growth outpacing revenue—if compliance capex spikes faster than margins expand, leverage gain stalls. Separately, Arthum's insurance partner integration and unit economics are worth tracking; early performance will signal whether the ₹20–30k Cr workforce financing market is as addressable as management claims.

Mufin Green Finance delivered a strong Q2—profitability inflected sharply, borrowing costs fell 265 bps, and the company has credibly pivoted to digital lending in structural markets. But the quarter is not a step-change; it is a proof-of-concept on a tightening timeline. Full-year PAT guidance of ₹80–90 Cr now rests on an H2 acceleration that management did not justify on the call, and the stock's 49% drawdown from its all-time high reflects this real execution risk. For holders, this is a Hold: the bull case is intact (cost discipline, digital mix, NPA improving, AUM on track), but the near-term bar is high. The single number to track from here is Q3 PAT growth—if it inflects 15%+ QoQ, the momentum compounds and a re-rating higher is earned. If Q3 grows slower, a guidance miss and downside repricing follow. The street has priced in debate; the next quarter resolves it.

Informational and educational content only. Not investment advice.